Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity-27 month follow-up results from Turkey
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol.253, no.10, pp.1677-1683, 2015 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 253 Issue: 10
- Publication Date: 2015
- Doi Number: 10.1007/s00417-014-2867-0
- Journal Name: GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.1677-1683
- Keywords: Retinopathy of prematurity (ROP), Anti-VEGF, Bevacizumab, Intravitreal injection, ZONE-I, COUNTRIES, LASER
- Karadeniz Technical University Affiliated: No
Abstract
To study the efficacy of intravitreal bevacizumab (IVB) injection as a single treatment for retinopathy of prematurity (ROP).